Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: A cost-effectiveness analysis

Clinical Drug Investigation

Volumn 34, Issue 1, 2014, Pages 9-17

  Rognoni, Carla ^a,b   Marchetti, Monia ^c   Quaglini, Silvana ^a   Liberato, Nicola Lucio ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b BOCCONI UNIVERSITY   (Italy)

^c CARDINAL MASSAIA HOSPITAL   (Italy)

^d Azienda Ospedaliera della Provincia di Pavia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEATH; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY OF LIFE; THROMBOEMBOLISM; AGED; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; HEALTH CARE COST; ITALY; PROBABILITY; STROKE; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COST-BENEFIT ANALYSIS; DRUG COSTS; FACTOR XA INHIBITORS; HEALTH CARE COSTS; HUMANS; ITALY; MARKOV CHAINS; MORPHOLINES; PYRAZOLES; PYRIDONES; QUALITY OF LIFE; STROKE; THIOPHENES; TREATMENT OUTCOME; WARFARIN;

EID: 84891871915     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0144-3     Document Type: Article

References (47)

1. Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke. 2001;32:392-8. (Pubitemid 32155224)
2. Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation: risk of stroke and role of antithrombotic therapy. Circulation. 1991;84:469-81.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-8.
4. Marini C, De Sanctis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36:1115-9. (Pubitemid 40803473)
5. Diringer MN, Edwards DF, Mattson DT, et al. Predictors of acute hospital costs for treatment of ischemic stroke in an academic center. Stroke. 1999;30:724-8. (Pubitemid 29156358)
6. Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart. 2004;90:286-92. (Pubitemid 38250721)
7. Ringborg A, Robby Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace. 2008;10:403-11. (Pubitemid 351767678)
8. McBride D, Mattenklotz AM, Willich SN, et al. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health. 2009;12:293-301.
9. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation. Arch Intern Med. 2012;172:623-31.
10. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67. (Pubitemid 351650486)
11. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429.
12. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e531S-75S.
13. Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke. 2011;42:112-8.
14. Di Pasquale G, Mathieu G, Maggioni AP, et al. Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA AF study. Int J Cardiol. 2013;167:2895-903.
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
16. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92.
17. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.
18. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events. Meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172:397-402.
19. Coyle D, Coyle K, Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16(4):498-506.
20. Oldgren J, Alings M, Darius H, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155:660-7.
21. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875-6.
22. Hudson M. Stroke prevention with atrial fibrillation. New oral anticoagulants. Available from: http://www.henryford.com/documents/Neurology/ Stroke%20Symposium/Atrial%20Fibrillation%20- %20New%20Anticoagulants%20and%20strategies-%20Hudson,MD.pdf (Accessed 9 Sep 2013).
23. Mahaffey KW, Fox KAA. Rocket AF. Available from: http://my.americanheart. org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-426788. pdf (Accessed 9 Sep 2013).
24. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-57.
25. Ariesen MJ, Claus SP, Rinkel GJ, et al. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34:2060-5. (Pubitemid 36944806)
26. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1-11.
27. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70. (Pubitemid 32537350)
28. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293(6):699-706. (Pubitemid 40216039)
29. Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164(8):880-4. (Pubitemid 38520629)
30. Monz BU, Connolly SJ, Korhonen M, et al. Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol. 2013. pii: S0167-5273(13)00478-6.
31. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke. 1998;29:1083-91. (Pubitemid 28265459)
32. Sullivan PW, Arant TW, Ellis SL, et al. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24:1021-33. (Pubitemid 44497473)
33. Meckley LM, Gudgeon JM, Anderson JL, et al. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 2010;28:61-74.
34. Fattore G, Torbica A, Susi A, et al. The social and economic burden of stroke survivors in Italy: a prospective, incident-based, multi-centre cost of illness study. BMC Neurol. 2012;12:137-47.
35. Piergentili P, Valle R, Milani L. Clinical and treatment profiles of patients affected by acute coronary syndromes derived from administrative databases in the ASSL 10 Veneto orientale. Monaldi Arch Chest Dis. 2011;76:33-42.
36. Fedele F, D'Ambrosi A, Bruno N, et al. Cost-effectiveness of levosimendan in patients with acute heart failure. J Cardiovasc Pharmacol. 2011;58:363-6.
37. AIFA - Agenzia Italiana del Farmaco - Determina 20 maggio 2013. Available from: http://www.gazzettaufficiale.it/atto/serie-generale/caricaDettaglioAtto/ originario?atto.dataPubblicazioneGazzetta=2013-06-01&atto.codiceRedazionale= 13A04727&elenco30giorni=true (Accessed 9 Sep 2013).
38. Briggs AH. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health. 2005;8:1-2. (Pubitemid 40293635)
39. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal; 2008. Available from: http://www.nice.org. uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (Accessed 9 Sep 2013).
40. Huang C, Siu M, Vu L, et al. Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation. J Eval Clin Pract. 2013;19:938-43.
41. Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 2011;343:d6333.
42. von Scheele B, Fernandez M, Hogue SL, et al. Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US. Ann Pharmacother. 2013;47:671-85.
43. Limone BL, Baker WL, Kluger J, et al. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One. 2013;8:e62183.
44. Kansal AR, Zheng Y, Pokora T, et al. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. Best Pract Res Clin Haematol. 2013;26:225-37.
45. Kansal AR, Sharma M, Bradley-Kennedy C, et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness. Thromb Haemost. 2012;108:672-82.
46. Harrington AR, Armstrong EP, Nolan PE Jr, et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676-81.
47. Sorensen SV, Peng S, Monz BU, et al. A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation. Pharmacoeconomics. 2013;31:589-604.